Locations:
Search IconSearch
January 5, 2023/Leadership

Reflections on Rheumatology ‘Year in Review’

Significant advances had a direct impact on clinical practice

patient consult

By Carol A. Langford, MD MHS

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

This year I was honored to be invited to provide the “Clinical Science Year in Review” at the American College of Rheumatology (ACR) Convergence 2022 meeting. Now that this lecture has come and gone, I have had an opportunity to reflect on what I learned. In addition to knowledge gained from the amazing works of published science, what I found took me back to why I chose to become a rheumatologist.

Medical advances

The past year brought forth significant advancements in rheumatology that had a direct impact on clinical practice or represented innovative approaches warranting further investigation. During this time, the Food and Drug Administration (FDA) approved six new indications impacting management of the spondyloarthritis family of diseases. In systemic lupus erythematosus, investigations included the first study of chimeric antigen receptor (CAR) T cells as well as phase 2 clinical trials of novel agents that target type I interferon pathways and B cells. Based on the results from a randomized trial of intravenous immunoglobulin on dermatomyositis, we also saw the first FDA-approved treatment for an inflammatory myositis. This body of work, as well as many other important contributions, demonstrate how progress in rheumatology continues to grow at a rapid pace.

Risk and benefit

As treatment options expand throughout the rheumatic diseases, weighing risk and benefit has become increasingly important. The assessment of risk needs to include not only short- and long-term toxicities related to the pharmacologic agent but also the risk of inadequately treated disease. During the past year, critical studies in rheumatoid arthritis examined the benefit/harm of glucocorticoids and the safety of a Janus kinase inhibitor. These studies reflect the commitment that rheumatology investigators and practitioners have made in seeking information that will inform shared decision-making with their patients.

Advertisement

Bench to bedside

An increased understanding of the pathophysiologic mechanisms of disease was fundamental to many of this year’s clinical trials in generating hypotheses for both efficacy and safety. While the opportunity for advancements through basic, translational and clinical research has never been greater, our ability to conduct such science has become increasingly difficult. The studies presented in the “Year in Review” exemplify how research funding as well support for junior and senior investigators is critical for future innovations in rheumatology.

The rheumatologist as patient advocate

An increased understanding of the pathophysiologic mechanisms of disease was fundamental to many of this year’s clinical trials in generating hypotheses for both efficacy and safety. While the opportunity for advancements through basic, translational and clinical research has never been greater, our ability to conduct such science has become increasingly difficult. The studies presented in the “Year in Review” exemplify how research funding as well support for junior and senior investigators is critical for future innovations in rheumatology.

The rheumatologist as patient advocate

Throughout the COVID pandemic, rheumatology professionals have played an essential role in providing both care and updated knowledge to their patients. The past year brought constant changes to which the rheumatology community responded. From vaccines to variants to novel pre-exposure prophylactic measures, it was the rheumatologist who our immunosuppressed patients turned to with their questions and concerns. Practicing rheumatologists applying information gained from the Global Rheumatology Alliance, the ACR COVID task force, and other international networks exemplified how our collective mission to keep patients safe can be accomplished by working together.

Advertisement

Rheumatology community

When first began to consider the “Year in Review,” it became clear that being able to select and present topics required not only an understanding of the individual publications but also the background behind each study. I sought to understand from others what they found important and meaningful during the past year and they in turn became my teachers. I reached out to a diverse spectrum of people: investigators in academic settings, rheumatologists in practice, trainees, and rheumatology health professionals. The response I received was staggering – all busy people, all wanting to help and to share their thoughts. It was only through their guidance that the “Year in Review” was possible.

When I chose to specialize in rheumatology, three key points motivated my decision: the rapid growth of scientific knowledge in the field, the ability to play an impactful role in the lives of patients, and the rheumatology community. What the “Year in Review” affirmed to me is that these elements are not only thriving today but will remain fundamental in propelling rheumatology into its exciting future.

Advertisement

Related Articles

Image of characters and scenes in Zen Quest
June 13, 2024/Leadership
Cleveland Clinic Enters the Metaverse to Support Mental Wellbeing

Interactive Zen Quest experience helps promote relaxing behaviors

Photo of Tom Mihaljevic, MD, and Gary Cohn
A Fireside Chat about Digital Technology in Healthcare

Cleveland Clinic and IBM leaders share insights, concerns, optimism about impacts

Computer screen graphic
How AI Assists With Staffing, Scheduling and Once-Tedious Tasks

Cleveland Clinic partners with Palantir to create logistical command center

Physician leaders
Research Guides Programs to Build Stronger Leaders

A Q&A with organizational development researcher Gina Thoebes

Health insurance, Doctor working in office at hospital and visual screen technology concept life insurance medical and heal care insurance concept
Finally: A Way to Measure Health Systems’ Investment in Quality

Cleveland Clinic transformation leader led development of benchmarking tool with NAHQ

Raed Dweik, MD
Effective Leadership Requires Listening (Podcast)

Raed Dweik, MD, on change management and the importance of communication

OPR_Aljeri_4134763_DEI Cohort Photos_8-17-23_LDJ
Building Connections Among Supplier Accelerator Alums

Small business owners expand their networks and gain new insights

Margaret McKenzie, MD
‘Look to Understand Rather Than To Be Understood’ (Podcast)

Leadership pearls from Margaret McKenzie, MD, hospital vice president

Ad